The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Prolonged and tunable residence time using reversible covalent kinase inhibitors
Open accessAbstract
Drugs with prolonged, on-target residence time often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking. Here, we demonstrate progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors. Utilizing an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, we identified potent and selective BTK inhibitors that demonstrate biochemical residence times spanning from minutes to 7 days. An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK more than 18 hours after clearance from the circulation. The inverted cyanoacrylamide strategy was further utilized to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating generalizability of the approach. Targeting noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates “residence time by design”, the ability to modulate and improve the duration of target engagement in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Quantitative reactivity profiling predicts functional cysteines in proteomes
Weerapana, E., Wang, C., Simon, G. M., Richter, F., Khare, S., Dillon, M. B. D., Bachovchin, D. A., Mowen, K., Baker, D., & Cravatt, B. F. (2010) · Nature · doi:10.1038/nature09472 · Cited by 1,684
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Self-citationDrug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909
Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Copeland, R. A. (2013) · Wiley eBooks · doi:10.1002/9781118540398 · Cited by 678
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 652
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., & Taunton, J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.925 · Cited by 493
Self-citationDrug–target residence time: critical information for lead optimization
Lu, H., & Tonge, P. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.176 · Cited by 432
The kinetics of competitive radioligand binding predicted by the law of mass action.
Motulsky, H. J., & Mahan, L. C. (1984) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)15016-5 · Cited by 414
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
Lanning, B. R., Whitby, L. R., Dix, M. M., Douhan, J., Gilbert, A. M., Hett, E. C., Johnson, T. O., Joslyn, C., Kath, J. C., Niessen, S., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1582 · Cited by 359
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Guagnano, V., Kauffmann, A., Wöhrle, S., Stamm, C., Ito, M., Barys, L., Pornon, A., Yao, Y., Li, F., Zhang, Y., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0210 · Cited by 347
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Di Paolo, J. A., Huang, T., Balazs, M., Barbosa, J., Barck, K. H., Bravo, B. J., Carano, R. A. D., Darrow, J., Davies, D. R., DeForge, L. E., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.481 · Cited by 340
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Barf, T., & Kaptein, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003203 · Cited by 331
Selinsky, B. S., Gupta, K., Sharkey, C. T., & Loll, P. J. (2001) · Biochemistry · doi:10.1021/bi010045s · Cited by 292
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702654104 · Cited by 284
Kapur, S., & Seeman, P. M. (2000) · PubMed · Cited by 284
The Use of AlphaScreen Technology in HTS: Current Status
Eglen, R. M., Reisine, T., Roby, P., Rouleau, N., Illy, C., Bossé, R., & Bielefeld, M. (2008) · Current Chemical Genomics · doi:10.2174/1875397300801010002 · Cited by 260
Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D., & Okazaki, O. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027797 · Cited by 251
Ibrutinib and novel BTK inhibitors in clinical development
Akinleye, A., Chen, Y., Mukhi, N., Song, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-59 · Cited by 229
Evans, E. K., Tester, R., Aslanian, S., Karp, R., Sheets, M., Labenski, M. T., Witowski, S. R., Lounsbury, H., Chaturvedi, P., Mazdiyasni, H., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203489 · Cited by 220
Copeland, R. A. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003677725 · Cited by 209
Evans, D. A., Ennis, M. D., Le, T., Mandel, N., & Mandel, G. (1984) · Journal of the American Chemical Society · doi:10.1021/ja00316a077 · Cited by 209
Drug discovery considerations in the development of covalent inhibitors
Mah, R., Thomas, J. R., & Shafer, C. M. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.10.003 · Cited by 193
Leproult, E., Barluenga, S., Moras, D., Wurtz, J.-M., & Winssinger, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101396q · Cited by 193
Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors
Miller, R. M., Paavilainen, V. O., Krishnan, S., Serafimova, I. M., & Taunton, J. (2013) · Journal of the American Chemical Society · doi:10.1021/ja401221b · Cited by 191
Self-citationTargeted covalent drugs of the kinase family
Singh, J., Petter, R. C., & Kluge, A. F. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.168 · Cited by 177
Drug discovery for a new generation of covalent drugs
Kalgutkar, A. S., & Dalvie, D. K. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.688744 · Cited by 166
Drug‐Target Residence Time—A Case for G Protein‐Coupled Receptors
Guo, D., Hillger, J. M., IJzerman, A. P., & Heitman, L. H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21307 · Cited by 166
Marcotte, D. J., Liu, Y., Arduini, R. M., Hession, C. A., Miatkowski, K., Wildes, C. P., Cullen, P. F., Hong, V. S., Hopkins, B. T., Mertsching, E., et al. (2010) · Protein Science · doi:10.1002/pro.321 · Cited by 158
Xu, D., Kim, Y. D., Postelnek, J., Vu, M. D., Hu, D., Liao, C., Bradshaw, M., Hsu, J., Zhang, J., Pashine, A., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187740 · Cited by 143
Self-citationA Structure-Guided Approach to Creating Covalent FGFR Inhibitors
Zhou, W., Hur, W., McDermott, U., Dutt, A., Xian, W., Ficarro, S. B., Zhang, J., Sharma, S. V., Brugge, J. S., Meyerson, M. M., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.02.007 · Cited by 135
Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis
Rankin, A. L., Seth, N., Keegan, S., Andreyeva, T., Cook, T. A., Edmonds, J., Mathialagan, N., Benson, M. J., Syed, J., Zhan, Y., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301553 · Cited by 113
Lou, Y. C., Owens, T. D., Kuglstatter, A., Kondru, R. K., & GOLDSTEIN, D. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300035p · Cited by 89
Self-citationTakakusa, H., Masumoto, H., Yukinaga, H., Makino, C., Nakayama, S., Okazaki, O., & Sudo, K. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021725 · Cited by 85
Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism
Vauquelin, G., Bostoen, S., Vanderheyden, P., & Seeman, P. M. (2012) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-012-0734-2 · Cited by 82
Development and Applications of a Broad-Coverage, TR-FRET-Based Kinase Binding Assay Platform
Lebakken, C. S., Riddle, S. M., Singh, U. P., Frazee, W. J., Eliason, H. C., Gao, Y. Q., Reichling, L. J., Marks, B. D., & Vogel, K. W. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109339207 · Cited by 82
Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
Wu, H., Wang, W., Liu, F., Weisberg, E., Tian, B., Chen, Y., Li, B., Wang, A., Wang, B., Zhao, Z., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb4008524 · Cited by 77
Vilums, M., Zweemer, A. J. M., Yu, Z., de Vries, H., Hillger, J. M., Wapenaar, H., Bollen, I. A. E., Barmare, F., Gross, R. S., Clemens, J. J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4011737 · Cited by 65
Swinney, D. C., Beavis, P. A., Chuang, K., Zheng, Y., Lee, I., Gee, P., Deval, J., Rotstein, D. M., Dioszegi, M., Ravendran, P., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12683 · Cited by 61
Louvel, J., Guo, D. M., Agliardi, M., Mocking, T. A. M., Kars, R., Pham, T. P., Xia, L., de Vries, H., Brussee, J., Heitman, L. H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401643m · Cited by 56
Can Binding Kinetics Translate to a Clinically Differentiated Drug? From Theory to Practice
Swinney, D. C. (2006) · Letters in Drug Design & Discovery · doi:10.2174/157018006778194754 · Cited by 55
Kuglstatter, A., Wong, A., Tsing, S., Lee, S. W., Lou, Y. C., Villaseñor, A. G., Bradshaw, J. M., Shaw, D. E., Barnett, J. W., & Browner, M. F. (2010) · Protein Science · doi:10.1002/pro.575 · Cited by 54
Self-citationModeling the Clinical Phenotype of BTK Inhibition in the Mature Murine Immune System
Benson, M. J., Rodriguez, V., von Schack, D., Keegan, S., Cook, T. A., Edmonds, J., Benoit, S., Seth, N. P., Du, S., Messing, D., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302570 · Cited by 33
Human telomeric G-quadruplex DNA interactions of N-phenanthroline glycosylamine copper(II) complexes
Duskova, K., Sierra, S., Arias, M. S., & Gude, L. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.11.037 · Cited by 28
Evans, D. A., Ennis, M. D., LE, T., Mandel, N. S., & Mandel, G. S. (1984) · ChemInform · doi:10.1002/chin.198421215 · Cited by 4
Cited by
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
The drug–target residence time model: a 10-year retrospective
Copeland, R. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.18 · Cited by 722
Metadata
- Authors
- Bradshaw, J. M., McFarland, J. M., Paavilainen, V. O., Bisconte, A., Tam, D., Phan, V. T., Romanov, S., Finkle, D., Shu, J., Patel, V., Ton, T., Li, X., Loughhead, D. G., Nunn, P. A., Karr, D. E., Gerritsen, M. E., Funk, J. O., Owens, T. D., Verner, E., Brameld, K. A., Hill, R. J., Goldstein, D. M., & Taunton, J.
- Venue
- Nature Chemical Biology
- Published
- 2015-05-25
- Volume
- 11
- Issue
- 7
- Pages
- 525-531
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W1526377515
- Cited by
- 422
- References
- 55
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.